We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Sun, Drugs, and Skin Cancer A Continuing Saga

Maria L. Chanco Turner, MD
Arch Dermatol. 2010;146(3):329-331. doi:10.1001/archdermatol.2010.25.
Text Size: A A A
Published online


Photocarcinogenesis continues to be an active field of investigation for dermatologists and photobiologists because of the continuing increased incidence of nonmelanoma skin cancers and of early cutaneous melanomas. Epidemiological and molecular studies provide supporting evidence that solar radiation is a major carcinogen for nonmelanoma skin cancers and melanomas. The wavelengths of UV radiation that reach the surface of the Earth and are able to penetrate skin consist of UV-B (280-315 nm) and UV-A (315-400 nm). Most of the UV radiation that reaches the Earth is UV-A. Only 5% to 10% is in the UV-B range. The major focus of investigations has been UV-B because it is thought to be the more carcinogenic wavelength by virtue of its ability to be directly absorbed by cellular DNA, directly causing damaging mutations in multiple tumor suppressor genes as well as diminishing the skin's immune responses. Mutations induced by UV-B are characterized by the presence of C → T or CC → TT patterns (cyclobutane pyrimidine dimers) and pyrimidine-pyrimidone 6-4 photoproducts (6-4 PP). These are quite specific to damage caused by UV and are referred to as “UV-signature mutations.” 1


skin cancer

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles